US equities
|
SPCX
$147.79
▲+0.00%
MU
$896.07
▲+0.00%
TSLA
$373.71
▲+0.00%
NVDA
$216.47
▲+0.00%
SNDK
$1,365.38
▲+0.00%
SKHY
$139.79
▲+0.00%
INTC
$91.69
▲+0.00%
AMD
$534.74
▲+0.00%
SPCX
$147.79
▲+0.00%
MU
$896.07
▲+0.00%
TSLA
$373.71
▲+0.00%
NVDA
$216.47
▲+0.00%
SNDK
$1,365.38
▲+0.00%
SKHY
$139.79
▲+0.00%
INTC
$91.69
▲+0.00%
AMD
$534.74
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Relmada Therapeutics, Inc. - Common Stock
(NQ:
RLMD
)
3.360
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Relmada Therapeutics, Inc. - Common Stock
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
August 11, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
August 06, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Relmada, Arrival, FMC, and Viasat and Encourages Investors to Contact the Firm
July 26, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Relmada, DoubleVerify, and Castle and Encourages Investors to Contact the Firm
July 21, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
July 16, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Chegg, and Relmada and Encourages Investors to Contact the Firm
July 10, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Chegg, and Relmada and Encourages Investors to Contact the Firm
July 05, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Seagate, Chegg, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
July 01, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Relmada, DoubleVerify, Sanmina, and JinkoSolar and Encourages Investors to Contact the Firm
June 25, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Seagate, Chegg, and Relmada and Encourages Investors to Contact the Firm
June 19, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
RLMD INVESTOR NEWS: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – RLMD
June 10, 2023
From
The Rosen Law Firm PA
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Relmada, Bowlero, and Integra and Encourages Investors to Contact the Firm
June 04, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Relmada, and Sanmina and Encourages Investors to Contact the Firm
May 19, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Fox, Cutera, and Relmada and Encourages Investors to Contact the Firm
May 14, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Investor Alert: Investigation Concerning Potential Securities Laws Violations
↗
May 11, 2023
San Diego, CA -- (SBWIRE) -- 05/11/2023 -- An investigation was announced for investors of Relmada Therapeutics, Inc. (NASDAQ:RLMD) shares over potential securities laws violations by Relmada...
Via
SBWire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Relmada Therapeutics, Inc. (RLMD) Investigation
May 11, 2023
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
RELMADA ALERT: Bragar Eagel & Squire, P.C. is Investigating Relmada Therapeutics, Inc. on Behalf of Relmada Stockholders and Encourages Investors to Contact the Firm
May 09, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
RLMD INVESTOR NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – RLMD
May 01, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
April 27, 2023
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
April 26, 2023
From
The Schall Law Firm
Via
Business Wire
Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028
May 26, 2022
Palm Beach, FL – May 26, 2022 – FinancialNewsMedia.com News Commentary – Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis,...
Via
FinancialNewsMedia
Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally
February 24, 2022
Palm Beach, FL –– February 24, 2022 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept...
Via
FinancialNewsMedia
Intranasal Ketamine Garnering A lot of Attention as an Effective Treatment For Depression
November 23, 2021
Palm Beach, FL –November 23, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic is expected to have a significant positive impact on the growth of the global antidepressant market....
Via
FinancialNewsMedia
